Clinical trials
Phase 1/2 trials in France with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 10 |
| Kartos Therapeutics, Inc. | 4 |
| Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 3 |
| Nantes University Hospital | 3 |
| Centre Hospitalier Universitaire de Nice | 2 |
| Cytheris SA | 2 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | 2 |
| Hospices Civils de Lyon | 2 |
| Institut Bergonié | 2 |
| University Hospital, Grenoble | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 5 |
| Melanoma | 5 |
| Breast Neoplasms | 3 |
| Hematologic Neoplasms | 3 |
| Brain Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Endometrial Neoplasms | 2 |
| Glioblastoma | 2 |
| Head and Neck Neoplasms | 2 |
| Hepatitis C | 2 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.